Dipal Doshi

Dipal has been Chief Executive Officer of Entrada Therapeutics and a Member of the Board of Directors since joining Entrada in 2017 as its first full-time employee shortly after the Company was founded and funded with seed capital. He previously served as President and Chief Executive Officer from 2017 to 2024.

Dipal has led many critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning and finance. Prior to joining Entrada, Dipal was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases that was acquired by BioMarin. He has also held senior level positions at a healthcare private equity fund and Catalent (acquired by Novo Holdings). Earlier in his career, Dipal worked in Merrill Lynch's Investment Banking Group and held several roles at Eli Lilly and Company.

Dipal holds an MBA from The Wharton School of the University of Pennsylvania and a BA from Rutgers University. He serves on the Board of Directors of the Biotechnology Innovation Organization (BIO), Azenta Life Sciences, a leading provider of life sciences solutions, and āshibio, a privately held, clinical-stage biotechnology company. He is also a Fellow of the Aspen Institute and serves on the Board of Advisors of Life Science Cares Boston.